European Society of Organ Transplantation (ESOT) Consensus Statement on Machine Perfusion in Cardiothoracic Transplant
Transplant International · 22.11.2024 · 37
DOI: 10.3389/ti.2024.13112 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Transplant International, online erschienen am 22.11.2024. Verfasst von Cristiano Amarelli und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac Surgery and Transplants, Monaldi, Azienda dei Colli, Naples, Italy. Hauptthemen laut MEDLINE: Perfusion, Heart Transplantation. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The machine perfusion (MP) of transplantable grafts has emerged as an upcoming field in Cardiothoracic (CT) transplantation during the last decade. This technology carries the potential to assess, preserve, and even recondition thoracic grafts before transplantation, so it is a possible game-changer in the field. This technology field has reached a critical turning point, with a growing number of publications coming predominantly from a few leading institutions, but still need solid scientific evidence. Due to the increasing need to expand the donor pool, especially in Europe, where the donor age is steeply increased, a consensus has been established to address the growing need and knowledge of machine perfusion in cardiothoracic transplantation, targeting the unmet scientific need in this growing field but also, priorities for development, and regional differences in utilization rates and organizational issues. To address MP in CT, the European Society of Organ Transplantation (ESOT) convened a dedicated Working group comprised of experts in CT to review literature about MP to develop guidelines that were subsequently discussed and voted on during the Consensus Conference that took place in person in Prague during the TLJ 3.0 in November 2022. The findings and recommendations of the Cardiothoracic Working Group on MP are presented in this article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiac Surgery and Transplants, Monaldi, Azienda dei Colli, Naples, Italy.
- Institut Clínic Respiratorio, Hospital Clinic of Barcelona, Barcelona, Spain.
- Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
- Transplant Unit, Royal Papworth Hospital, NHS Foundation Trust, Cambridge, United Kingdom.
- Cardiac Surgery Division, Surgical Sciences Department, Citta della Salute e della Scienza, University of Torino, Turin, Italy.
- Department Cardiothoracic Transplant, Newcastle University, Newcastle upon Tyne, United Kingdom.
Zitieren
APA
Amarelli, C., Bello, I., Aigner, C., Berman, M., Boffini, M., Clark, S., Dalvindt, M., de Wolf, J., Ensminger, S., Gomez de Antonio, D., Hoyos, L., Palmieri, L., Schweiger, M., Sponga, S., Wiegmann, B., Neyrinck, A., & ESOT Guidelines Taskforce (2024). European Society of Organ Transplantation (ESOT) Consensus Statement on Machine Perfusion in Cardiothoracic Transplant. Transplant International, 37. https://doi.org/10.3389/ti.2024.13112
Vancouver
Amarelli C, Bello I, Aigner C, Berman M, Boffini M, Clark S, et al. European Society of Organ Transplantation (ESOT) Consensus Statement on Machine Perfusion in Cardiothoracic Transplant. Transplant International. 2024;37. doi:10.3389/ti.2024.13112
BibTeX
@article{Amarelli2024,
author = {Amarelli, Cristiano and Bello, Irene and Aigner, Clemens and Berman, Marius and Boffini, Massimo and Clark, Stephen and Dalvindt, Marita and de Wolf, Julien and Ensminger, Stephan and Gomez de Antonio, David and Hoyos, Lucas and Palmieri, Lucrezia and Schweiger, Martin and Sponga, Sandro and Wiegmann, Bettina and Neyrinck, Arne and ESOT Guidelines Taskforce, ESOT Guidelines Taskforce},
title = {European Society of Organ Transplantation (ESOT) Consensus Statement on Machine Perfusion in Cardiothoracic Transplant},
journal = {Transplant International},
year = {2024},
volume = {37},
doi = {10.3389/ti.2024.13112}
}
EUVIMED